Comparison of the treatment outcomes: percent change in the sum of longest diameters (RECIST) and percent change of the lesion with the highest SUL (PERCIST) between standard therapy plus Lu-177 PSMA ligand therapy and standard therapy alone among patients with prostatic cancer status-post castration using Ga-18 PET-CT as an outcome indicator
- Author:
Miguel Antonio C. Catangui
1
;
Irene S. Bandong
1
;
Eric B. Cruz
1
;
Carl Johnry J. Santos
1
;
Jonathan Edward A. Layno
1
Author Information
1. Department of Nuclear Medicine and Theranostics, St. Lukes Medical Center-Quezon City
- Publication Type:Journal Article
- Keywords:
Lu-177 PSMA;
Ga-68 PSMA
- MeSH:
Prostatic Neoplasms
- From:
The Philippine Journal of Nuclear Medicine
2023;18(1):8-16
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Prostate cancer is the third most common cancer among Filipino males. Ga-68 PSMA PET-CT and Lu-177 PRLT have been introduced in the Philippines for the diagnostics and therapy of prostate cancer.
Objective:The aim of this study is to compare treatment outcomes of standard therapy plus Lu-177 PSMA radioligand therapy and standard therapy alone among patients with prostatic cancer status-post castration using Ga-68 PET-CT as an outcome indicator.
Methodology:This is an ambispective cohort study on Ga-68 PSMA PET-CT scans performed between January 1, 2018 and July
31, 2021. Serum PSA data taken within one month of the PET-CT scans were also collected when available. The
PET-CT images were reviewed by a radiologist for RECIST response, and by a nuclear medicine physician for
PERCIST response .
Results:A total of 11 participants were included in the study. Six participants (55.5%) received standard therapy, while
five participants (45.5%) received Lu-177 PSMA radioligand therapy plus standard therapy. There was no
significant difference in the baseline and follow-up CT as shown by all p values > 0.05. A trend towards higher
number of participants with non-complete/non-progressive RECIST response was noted in the control group
than the treatment group, as well as higher number of participants with progressive or stable disease using the
PERCIST response.
Conclusion:There were no significant differences noted in the clinical outcomes of participants who received Lu-177 PRLT
and those with standard therapy alone. A trend towards decreasing serum PSA, CT and PET measurements
were noted among patients given Lu-177 PRLT than those with standard therapy.
- Full text:18 (1) article 1.pdf
